Ovarian cancer
Not yet recruitingPhase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy
Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy
- Disease:Ovarian cancer
- Substances:BevacizumabTrastuzumab Deruxtecan
Spain- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico








